Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17533512 | 0.96 | FOLH1 (0.47) | FOLH1MAPTALDH1A1KMT2AGAA | |
| SCHEMBL19220639 | 0.91 | FOLH1 (0.55) | FOLH1LMNAMAOB | |
| SCHEMBL21919736 | 0.90 | FOLH1 (0.43) | FOLH1MAPTALDH1A1KMT2AGAA | |
| SCHEMBL19220633 | 0.87 | LMNA (0.36) | FOLH1LMNAMAPTALDH1A1MAOB | |
| SCHEMBL19220650 | 0.87 | FOLH1 (0.45) | FOLH1LMNAMAPTALDH1A1MAOB | |
| SCHEMBL17533511 | 0.86 | FOLH1 (0.59) | FOLH1 | |
| SCHEMBL21919745 | 0.85 | FOLH1 (0.46) | FOLH1KMT2APOLB | |
| SCHEMBL19220641 | 0.85 | LMNA (0.36) | FOLH1LMNAMAPTALDH1A1MAOB | |
| SCHEMBL19220638 | 0.84 | LMNA (0.37) | FOLH1LMNAMAPTALDH1A1MAOB | |
| SCHEMBL29520333 | 0.83 | FOLH1 (0.47) | FOLH1MAPTALDH1A1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988407-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | FOLH1 1/4885LMNA 1683/4885MAPT 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.